This renowned congress will bring together over 250 attendees from pharmaceutical and biotechnology companies as well as academia. Over 55 presentations, case studies and panel discussions focused on the key issues in biomarker research, companion diagnostics, personalised medicine and clinical biomarkers.
Going into its 11th year, Europe’s leading biomarkers congress will include representatives from the top pharmaceutical companies including AstraZeneca, Roche, BMS, Merck, AbbVie and top service provide companies including QuartzBio, MesoScaleDiscovery, LGC, Almac and more. Our expert speaker panel will also consist of renowned academics and smaller pharmaceutical companies who will bring their unique stories to the programme.
New for 2016, the updated agenda will cover case studies from a range of therapeutic areas including, oncology, immune-oncology, metabolic diseases, autoimmune diseases, fibrotic disorders, diabetes and more in the pre-clinical and clinical arena. We will cover presentations on why NGS is the choice of diagnostics by Professor Bill Newman, Genomics England, microRNAs as a potential circulating biomarker of drug-induced liver injury by Professor Kevin Park, University of Liverpool.
Additional pre-clinical topic areas include the potential of metabolomics profiling to understand disease process and therapy by Marianne Manchester, F. Hoffman-La Roche; outsourcing clinical trials with companion diagnostics: new insights for service providers by Sophie Wildsmith, Roche.
Download the conference programme by clicking here